Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | QDPR | P09417 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2998445 | 0.82 | CYP1A2 (0.44) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL21846307 | 0.80 | EPHX2 (0.43) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL453485 | 0.79 | — | — | |
| SCHEMBL24434580 | 0.78 | EPHX2 (0.42) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL14317303 | 0.78 | EPHX2 (0.42) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL21577629 | 0.77 | ALDH1A1 (0.32) | — | |
| SCHEMBL5006495 | 0.77 | KDM1A (0.33) | — | |
| SCHEMBL22919353 | 0.77 | EPHX2 (0.49) | EPHX2EPHX1 | |
| SCHEMBL2666145 | 0.77 | EPHX2 (0.53) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL4239689 | 0.77 | MEN1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233920-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | claimed |
| CN-101223140-A | Piperidine derivatives useful in the diagnostic and therapeutic treatment of diseases depending on renin activity | NOVARTIS AG (CH) | 2008-07-16 | — | — | CN | claimed |
| EP-1907359-A2 | 3,5-SUBSTITUTED PIPERIDINE DERIVATIVES EFFECTIVE ON RENIN-RELATED DISORDERS | Novartis AG (CH) | 2008-04-09 | — | — | EP | claimed |
| WO-2007006534-A2 | PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY | NOVARTIS AG (CH) | 2007-01-18 | — | — | WO | claimed |
| US-6967197-B2 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-22 | — | — | US | claimed |
| CN-1188404-C | Cyclic compound | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-02-09 | — | — | CN | claimed |
| US-6660858-B2 | Made by reacting a benzoxazole with a leaving group at the 2 position and a diamine of given formula | LION BIOSCIENCE AG (DE) | 2003-12-09 | — | — | US | claimed |
| US-20030134849-A1 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | US | claimed |
| CN-1425010-A | Cyclic compound | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-06-18 | — | — | CN | claimed |
| US-20020161028-A1 | 2-aminobenzoxazole derivatives and combinatorial libraries thereof | LION BIOSCIENCE, AG (DE) | 2002-10-31 | — | — | US | claimed |
| WO-2002079753-A2 | 2-AMINOBENZOXAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2002-10-10 | — | — | WO | claimed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | claimed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | claimed |
| US-12503468-B2 | Heterocyclic compound, intermediate, preparation method therefor and application thereof | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| EP-4626426-A1 | COMBINATIONS COMPRISING A MENIN-MLL INHIBITOR AND AT LEAST ONE OTHER THERAPEUTIC AGENT | JANSSEN Pharmaceutica NV (BE) | 2025-10-08 | — | — | EP | disclosed |
| EP-4626427-A1 | COMBINATIONS COMPRISING A MENIN-MLL INHIBITOR AND A BCL-2 INHIBITOR | Janssen Pharmaceutica NV (BE) | 2025-10-08 | — | — | EP | disclosed |
| WO-1994001113-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-01-20 | — | — | WO | disclosed |
| US-5225402-A | Vasopressin antagonist, vasodilation, hypotensive, diuretics and anticoagulants | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-06 | — | — | US | disclosed |
| EP-0382185-A2 | Carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161028-A1 | 2-aminobenzoxazole derivatives and combinatorial libraries thereof | BCAT2, IL4I1, BCAT1 | CYP1A2 351/4885TDP1 3232/4885EPHX2 1458/4885 |
| US-20090233920-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | CYP1A2 261/4885TDP1 2675/4885EPHX2 1323/4885 |
| US-12503468-B2 | Heterocyclic compound, intermediate, preparation method therefor and application thereof | P2RX3, P2RX7, P2RX4 | CYP1A2 895/4885TDP1 2579/4885EPHX2 1153/4885 |
| US-20030134849-A1 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | MMP9, MMP1, MMP3 | CYP1A2 2174/4885TDP1 3418/4885EPHX2 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.